Poor AstraZeneca. No crown for Crestor!
Yesterday they were dealt a blow in their efforts to expand sales of its underperforming cholesterol-lowering drug Crestor, with the publication of disappointing clinical trial results for the drug's use in protecting against advanced heart failure.
Data presented at the American Heart Association meeting in Orlando, Florida, showed that Crestor - or rosuvastatin - did not significantly reduce the number of deaths.
Analysts said that a successful result in the long-awaited “CORONA” study of more than 5,000 patients, could have boosted sales of Crestor by $1 billion (£480 million) in the US alone and would have allowed AstraZeneca to apply for an extension to the drug’s patent life.
But AstraZeneca said the trial showed that adding Crestor to the standard drug treatment for heart failure had failed to show any reversal of heart muscle damage.
More
Insider's view: Hands up at AZ: who honestly thought CORONA was a good idea?
Yesterday they were dealt a blow in their efforts to expand sales of its underperforming cholesterol-lowering drug Crestor, with the publication of disappointing clinical trial results for the drug's use in protecting against advanced heart failure.
Data presented at the American Heart Association meeting in Orlando, Florida, showed that Crestor - or rosuvastatin - did not significantly reduce the number of deaths.
Analysts said that a successful result in the long-awaited “CORONA” study of more than 5,000 patients, could have boosted sales of Crestor by $1 billion (£480 million) in the US alone and would have allowed AstraZeneca to apply for an extension to the drug’s patent life.
But AstraZeneca said the trial showed that adding Crestor to the standard drug treatment for heart failure had failed to show any reversal of heart muscle damage.
More
Insider's view: Hands up at AZ: who honestly thought CORONA was a good idea?
No comments:
Post a Comment